Compare ProShares UltraPro QQQ ETF (TQQQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? ProShares UltraPro QQQ ETF trades at $71.71 (market cap $38.26B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 7.8× Travere Therapeutics Inc. Common Stock's market cap, and ProShares UltraPro QQQ ETF is more actively traded (38,965,303 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 25 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TQQQ | TVTX | |
|---|---|---|
Market Cap | $38.26B | $4.88B |
Volume | 38,965,303 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $67.52 |
52-Week Low | $37.89 | $26.79 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $78.81, down 1.0% on the day, with a bullish technical signal from moving averages but neutral oscillators. The leveraged ETF faces mixed sentiment with recent articles highlighting both strong performance during the AI boom and concerns about hidden costs and volatility decay. Support levels are established at $77-$79, with resistance at $81-$82.
The outlook remains volatile with 3x leverage amplifying both gains and losses. Key risks include expense ratios beyond the stated 0.82% and market volatility amplification. Institutional activity shows mixed positioning, with some firms reducing stakes while others add exposure to tech and AI themes.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
